Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics (NASDAQ:CYTX) is reporting its financial results for the year ended December 31, 2009. More information on our commercial and clinical progress is posted online in the ‘March 2010 Shareholder Letter’ at http://ir.cytoritx.com/investorrelations/blog.

During 2009, Cytori achieved the following:

  • Grew system and consumable sales, predominantly into the cosmetic surgery market;
  • Increased number of systems in the field that will further support consumable cartridge sales growth;
  • Reported interim results from a post-marketing breast reconstruction study intended to support cosmetic and reconstructive surgery sales efforts in Europe and Asia;
  • Expanded autologous fat graft product line with development of the PureGraft™ System (which received FDA clearance early 2010); and
  • Completed enrollment in two cardiovascular disease safety and feasibility trials with results to be reported in May 2010.

System and Consumables

Throughout 2009, we more than doubled the cumulative number of ‘revenue base’ systems, which includes systems sold directly to physicians, distributors or units placed that are generating consumable sales. At the end of 2009, the cumulative number of revenue base systems was 101, compared to 85 at the end of the third quarter of 2009, and 42 at the end of 2008. In addition, a total of 337 consumables were shipped in the fourth quarter of 2009 compared to 314 consumables shipped in the third quarter of 2009 and 179 consumables shipped in the fourth quarter of 2008. Of these, 258 consumables were re-orders in the fourth quarter of 2009, compared to 185 re-orders in the third quarter of 2009. This reflects a positive trend whereby existing customers are contributing to a greater percent of consumable revenues.

Financial Results

Total revenues for the year ending December 31, 2009 were $14.7 million, which consisted of $8.9 million in development revenues, related mostly to the achievement of three clinical milestones under our Olympus Corporation partnership, and $5.8 million in product revenues. This compares to total revenues of $6.9 million for 2008, which consisted of $2.3 million in development revenues and $4.5 million in product revenues in 2008. Gross profit for 2009 was $2.4 million compared to $2.7 million for 2008.

Total revenues for the fourth quarter of 2009 were $2.9 million, which consisted of $1.6 million in development revenue and $1.3 million in product revenues. This compares to $2.2 million in total revenues in the fourth quarter of 2008, which consisted of $1.5 million in development revenue and $652,000 in product revenue. Gross profit was $513,000 in the fourth quarter of 2009, compared to $181,000 for the same period in 2008.

Total operating expenses for 2009 were $32.9 million compared to $34.8 million in 2008. Approximately $9.2 million of total expenses in 2009 were non-cash, including $6.3 million in non-cash expenses related to the increase in fair value of warrants and stock based compensation offset by a reduction in the fair value of the option liability. In comparison, approximately $4.8 million of total expenses were non-cash in 2008. In 2009, there was a significant reduction in operating expenses driven by $6.5 million of reductions in research and development and general and administrative expenses offset in part by a $2.0 increase in sales and marketing expenses. Net cash used in operating activities for the fourth quarter and full year 2009 was $6.1 million and $23.8 million respectively, compared to $7.3 million and $33.4 million, respectively in 2008.

Balance Sheet

Cytori ended the year 2009 with $12.9 million in cash and cash equivalents plus $1.6 million in accounts receivable, compared to $12.6 million in cash and cash equivalents and $1.3 million in accounts receivable as of December 31, 2008. Subsequent to end of the year, Cytori raised $14.3 million from scheduled closings with Seaside 88, LP and the exercise by third parties of the warrants trading under the symbol CYTXW. Cytori believes that based on its anticipated gross profits, cash operating requirements and proceeds from Seaside 88, the Company has sufficient funds through the first half of 2011.

Source:

Cytori

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Olympus Life Science Solutions. (2019, June 24). Cytori Therapeutics reports total revenues of $14.7M for 2009. News-Medical. Retrieved on April 20, 2021 from https://www.news-medical.net/news/20100312/Cytori-Therapeutics-reports-total-revenues-of-24147M-for-2009.aspx.

  • MLA

    Olympus Life Science Solutions. "Cytori Therapeutics reports total revenues of $14.7M for 2009". News-Medical. 20 April 2021. <https://www.news-medical.net/news/20100312/Cytori-Therapeutics-reports-total-revenues-of-24147M-for-2009.aspx>.

  • Chicago

    Olympus Life Science Solutions. "Cytori Therapeutics reports total revenues of $14.7M for 2009". News-Medical. https://www.news-medical.net/news/20100312/Cytori-Therapeutics-reports-total-revenues-of-24147M-for-2009.aspx. (accessed April 20, 2021).

  • Harvard

    Olympus Life Science Solutions. 2019. Cytori Therapeutics reports total revenues of $14.7M for 2009. News-Medical, viewed 20 April 2021, https://www.news-medical.net/news/20100312/Cytori-Therapeutics-reports-total-revenues-of-24147M-for-2009.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The Olympus scanR High-Content Screening Station Rapidly Acquires Quantitative Data from Cell-Based Assays